Request for Information for the Development of the Fiscal Year 2021-2023 Trans-NIH Strategic Plan for HIV and HIV-Related Research, 23471-23472 [2018-10784]

Download as PDF sradovich on DSK3GMQ082PROD with NOTICES Federal Register / Vol. 83, No. 98 / Monday, May 21, 2018 / Notices determined as follows: (1) Primary medical care HPSAs with scores of 18 and above are authorized for the assignment of NHSC scholars who are primary care physicians, primary care nurse practitioners, primary care physician assistants, or certified nurse midwives; (2) mental health HPSAs with scores of 18 and above are authorized for the assignment of NHSC scholars who are psychiatrists, mental health nurse practitioners, or mental health physician assistants; and (3) dental HPSAs with scores of 18 and above are authorized for the assignment of NHSC scholars who are dentists. The NHSC has determined that a minimum HPSA score of 18 for all service-ready NHSC scholars will enable it to meet its statutory obligation to identify a number of entities eligible for NHSC scholar placement that is at least equal to, but not greater than, twice the number of NHSC scholars available to serve in the 2018–2019 placement cycle. Beginning on April 1, 2019, and on or about April 1 of each subsequent year, HRSA will publish on its website https://connector.hrsa.gov/, the HPSA scores used to determine priority for assignment of NHSC scholars for placement cycles after September 30, 2019, and entities that would receive priority for the placement of NHSC scholars. Entities wishing to provide additional data and information to support their inclusion on the proposed list of entities receiving priority in assignment of NHSC scholars, or to support a higher priority determination, must do so in writing no later than May 1, 2019, or within 30 days following the publication of a revised list in subsequent years. Sites wishing to request an additional scholar must complete an Additional Scholar Request form available at https:// nhsc.hrsa.gov/downloads/additional requestform.pdf. NHSC-approved sites that do not meet the authorized threshold HPSA may post job openings on the Health Workforce Connector; however, scholars seeking placement will be advised that they can only compete for positions at sites that meet the threshold that is in effect at the time they seek to be placed at an NHSCapproved site. Although vacancies in HPSAs that have scores less than the authorized threshold are not eligible for scholar placements, such vacancies will be used by the NHSC when evaluating the HPSA threshold score for the next annual scholarship placement cycle. Application Requests The list of HPSAs and entities eligible to receive priority for the placement of NHSC scholars is updated periodically. VerDate Sep<11>2014 18:20 May 18, 2018 Jkt 244001 New entities may be added to the Health Workforce Connector during a Site Application competition. Likewise, entities that no longer meet eligibility criteria, including those sites whose 3year approval as an NHSC service site has lapsed or whose HPSA designation has been withdrawn or whose withdrawal is being processed, will be removed from the priority listing. Dated: May 15, 2018. George Sigounas, Administrator. [FR Doc. 2018–10699 Filed 5–18–18; 8:45 am] BILLING CODE 4165–15–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Request for Information for the Development of the Fiscal Year 2021– 2023 Trans-NIH Strategic Plan for HIV and HIV-Related Research AGENCY: National Institutes of Health, HHS. ACTION: Notice. Through this Request for Information (RFI), the Office of AIDS Research (OAR) in the Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI), National Institutes of Health (NIH), invites feedback from investigators in academia, industry, health care professionals, patient advocates and health advocacy organizations, scientific or professional organizations, federal agencies, community, and other interested constituents on the development of the fiscal year (FY) 2021–2023 Trans-NIH Strategic Plan for HIV and HIV-Related Research (the Plan). The Plan is designed to identify and articulate future directions to maximize the NIH’s investments in HIV research. DATES: The OAR’s Request for Information is open for public comment for a period of 30 days. Comments must be received by June 20, 2018 to ensure consideration. After the public comment period has closed, the comments received by OAR will be considered in a timely manner for the development of the FY 2021–2023 Trans-NIH Strategic Plan for HIV and HIV-related Research. ADDRESSES: Submissions may be electronically entered at https:// grants.nih.gov/grants/rfi/rfi.cfm?ID=76. FOR FURTHER INFORMATION CONTACT: Questions about this request for information should be directed to the Office of AIDS Research, National SUMMARY: PO 00000 Frm 00058 Fmt 4703 Sfmt 4703 23471 Institutes of Health, email: NIHOARRFI@nih.gov, 5601 Fishers Lane Rockville, Maryland 20852. SUPPLEMENTARY INFORMATION: To respond this RFI, go to the following web address: https://grants.nih.gov/ grants/rfi/rfi.cfm?ID=76. As legislatively mandated, OAR plans and coordinates research through the development of an annual Trans-NIH Strategic Plan for HIV and HIV-Related Research that articulates the overarching HIV research priorities and serves as the framework for developing the trans-NIH HIV research budget. OAR oversees and coordinates the conduct and support of all HIV research activities across the NIH Institutes and Centers (ICs). The NIH-sponsored HIV research programs include both extramural and intramural research, buildings and facilities, research training, program evaluation, and supports a comprehensive portfolio of research representing a broad range of basic, clinical, behavioral, social sciences, and translational research on HIV and its associated coinfections and comorbidities. The Plan provides information about the NIH’s HIV research priorities to the scientific community, Congress, community stakeholders, HIV-affected communities, and the broad public at large. The fiscal year 2018 Trans-NIH Plan for HIV-Related Research was recently distributed on the OAR website: (https://www.oar.nih.gov/ strategic_plan/plan_18.asp). The current overarching priorities for HIV/AIDS research are defined in the NIH Director’s Statement of August 12, 2015, and Guide Notice NOT–OD–15– 137 (https://grants.nih.gov/grants/ guide/notice-files/NOT-OD-15137.html). High Priority topics of research for support include: (1) Reducing the incidence of HIV/ AIDS; (2) Developing the next generation of HIV therapies; (3) Identifying strategies towards a cure; (4) Improving the prevention and treatment of HIV-associated comorbidities, coinfections, and complications; and (5) Cross-cutting areas that includes basic research, behavioral and social sciences research, health disparities, trainings, capacity-building, and infrastructure. This RFI is for planning purposes only and should not be construed as a solicitation for applications or proposals, or as an obligation in any way on the part of the United States Federal Government. The Federal E:\FR\FM\21MYN1.SGM 21MYN1 23472 Federal Register / Vol. 83, No. 98 / Monday, May 21, 2018 / Notices Government will not pay for the preparation of any information submitted or for the government’s use. Additionally, the government cannot guarantee the confidentiality of the information provided. Dated: May 14, 2018. Lawrence A. Tabak, Deputy Director, National Institutes of Health. [FR Doc. 2018–10784 Filed 5–18–18; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meetings sradovich on DSK3GMQ082PROD with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR Panel: Neural Regulation of Cancer. Date: June 7, 2018. Time: 2:00 p.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Manzoor Zarger, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6208, MSC 7804, Bethesda, MD 20892, (301) 435– 2477, zargerma@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Program Projects: Drug Abuse. Date: June 8, 2018. Time: 11:00 a.m. to 2:00 p.m. Agenda: To review and evaluate grant applications. Place: Sheraton Seattle Hotel, 1400 6th Avenue, Seattle, WA 98101. Contact Person: Jasenka Borzan, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive Room 4214, Bethesda, MD 20892–7814, 301–435–1787, borzanj@csr.nih.gov. Name of Committee: Biological Chemistry and Macromolecular Biophysics Integrated VerDate Sep<11>2014 18:20 May 18, 2018 Jkt 244001 Review Group; Macromolecular Structure and Function D Study Section. Date: June 13, 2018. Time: 9:00 a.m. to 8:00 p.m. Agenda: To review and evaluate grant applications. Place: The Allerton Hotel, 701 North Michigan Avenue, Chicago, IL 60611. Contact Person: James W. Mack, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4154, MSC 7806, Bethesda, MD 20892, (301) 435– 2037, mackj2@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Rodent Testing Centers for Development of Reporter Systems and Evaluation of Somatic Cell Genome Editing Tools (U42). Date: June 13, 2018. Time: 10:30 a.m. to 11:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Alok Mulky, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4203, Bethesda, MD 20892, (301) 435–3566, alok.mulky@nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Academic Research Enhancement Award. Date: June 13, 2018. Time: 1:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Reigh-Yi Lin, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, 301–827–6009, lin.reigh-yi@nih.gov. Name of Committee: Immunology Integrated Review Group; Transplantation, Tolerance, and Tumor Immunology Study Section. Date: June 14–15, 2018. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Washington Plaza Hotel, 10 Thomas Circle NW, Washington, DC 20005. Contact Person: Jin Huang, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4199, MSC 7812, Bethesda, MD 20892, 301–435– 1230, jh377p@nih.gov. Name of Committee: Biological Chemistry and Macromolecular Biophysics Integrated Review Group; Macromolecular Structure and Function C Study Section. Date: June 14, 2018. Time: 8:00 a.m. to 7:00 p.m. Agenda: To review and evaluate grant applications. Place: The Allerton Hotel, 701 North Michigan Avenue, Chicago, IL 60611. Contact Person: William A. Greenberg, Ph.D., Scientific Review Officer, Center for PO 00000 Frm 00059 Fmt 4703 Sfmt 4703 Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4168, MSC 7806, Bethesda, MD 20892, (301) 435– 1726, greenbergwa@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Auditory Science. Date: June 14, 2018. Time: 8:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: Washington Marriott Georgetown, 1221 22nd Street NW, Washington, DC 20037. Contact Person: Jana Drgonova, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5213, Bethesda, MD 20892, 301–827–2549, jdrgonova@mail.nih.gov. Name of Committee: Healthcare Delivery and Methodologies Integrated Review Group; Biostatistical Methods and Research Design Study Section. Date: June 14–15, 2018. Time: 8:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: Embassy Suites by Hilton Chicago Downtown, 600 North State Street, Chicago, IL 60654. Contact Person: Peter J. Kozel, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3139, Bethesda, MD 20892, 301–435–1116, kozelp@ mail.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Respiratory Sciences. Date: June 14–15, 2018. Time: 9:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Ghenima Dirami, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4122, MSC 7814, Bethesda, MD 20892, 240–498– 7546, diramig@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Par Panel: Academic-Industrial Partnerships Research for Cancer Diagnosis and Treatment. Date: June 15, 2018. Time: 8:30 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. Contact Person: Guo Feng Xu, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5122, MSC 7854, Bethesda, MD 20892, 301–237– 9870, xuguofen@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) E:\FR\FM\21MYN1.SGM 21MYN1

Agencies

[Federal Register Volume 83, Number 98 (Monday, May 21, 2018)]
[Notices]
[Pages 23471-23472]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-10784]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Request for Information for the Development of the Fiscal Year 
2021-2023 Trans-NIH Strategic Plan for HIV and HIV-Related Research

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Through this Request for Information (RFI), the Office of AIDS 
Research (OAR) in the Division of Program Coordination, Planning, and 
Strategic Initiatives (DPCPSI), National Institutes of Health (NIH), 
invites feedback from investigators in academia, industry, health care 
professionals, patient advocates and health advocacy organizations, 
scientific or professional organizations, federal agencies, community, 
and other interested constituents on the development of the fiscal year 
(FY) 2021-2023 Trans-NIH Strategic Plan for HIV and HIV-Related 
Research (the Plan). The Plan is designed to identify and articulate 
future directions to maximize the NIH's investments in HIV research.

DATES: The OAR's Request for Information is open for public comment for 
a period of 30 days. Comments must be received by June 20, 2018 to 
ensure consideration. After the public comment period has closed, the 
comments received by OAR will be considered in a timely manner for the 
development of the FY 2021-2023 Trans-NIH Strategic Plan for HIV and 
HIV-related Research.

ADDRESSES: Submissions may be electronically entered at https://grants.nih.gov/grants/rfi/rfi.cfm?ID=76.

FOR FURTHER INFORMATION CONTACT: Questions about this request for 
information should be directed to the Office of AIDS Research, National 
Institutes of Health, email: [email protected], 5601 Fishers Lane 
Rockville, Maryland 20852.

SUPPLEMENTARY INFORMATION: To respond this RFI, go to the following web 
address: https://grants.nih.gov/grants/rfi/rfi.cfm?ID=76.
    As legislatively mandated, OAR plans and coordinates research 
through the development of an annual Trans-NIH Strategic Plan for HIV 
and HIV-Related Research that articulates the overarching HIV research 
priorities and serves as the framework for developing the trans-NIH HIV 
research budget. OAR oversees and coordinates the conduct and support 
of all HIV research activities across the NIH Institutes and Centers 
(ICs). The NIH-sponsored HIV research programs include both extramural 
and intramural research, buildings and facilities, research training, 
program evaluation, and supports a comprehensive portfolio of research 
representing a broad range of basic, clinical, behavioral, social 
sciences, and translational research on HIV and its associated 
coinfections and comorbidities.
    The Plan provides information about the NIH's HIV research 
priorities to the scientific community, Congress, community 
stakeholders, HIV-affected communities, and the broad public at large. 
The fiscal year 2018 Trans-NIH Plan for HIV-Related Research was 
recently distributed on the OAR website: (https://www.oar.nih.gov/strategic_plan/plan_18.asp).
    The current overarching priorities for HIV/AIDS research are 
defined in the NIH Director's Statement of August 12, 2015, and Guide 
Notice NOT-OD-15-137 (https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-137.html).
    High Priority topics of research for support include:
    (1) Reducing the incidence of HIV/AIDS;
    (2) Developing the next generation of HIV therapies;
    (3) Identifying strategies towards a cure;
    (4) Improving the prevention and treatment of HIV-associated 
comorbidities, coinfections, and complications; and
    (5) Cross-cutting areas that includes basic research, behavioral 
and social sciences research, health disparities, trainings, capacity-
building, and infrastructure.
    This RFI is for planning purposes only and should not be construed 
as a solicitation for applications or proposals, or as an obligation in 
any way on the part of the United States Federal Government. The 
Federal

[[Page 23472]]

Government will not pay for the preparation of any information 
submitted or for the government's use. Additionally, the government 
cannot guarantee the confidentiality of the information provided.

    Dated: May 14, 2018.
Lawrence A. Tabak,
Deputy Director, National Institutes of Health.
[FR Doc. 2018-10784 Filed 5-18-18; 8:45 am]
 BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.